Patients with type 2 diabetes mellitus (T2DM) and elevated cardiovascular (CV) risk benefit from interventions that significantly reduce major CV events, myocardial infarctions, and strokes. Clinical trials such as CARDS Trial highlight reductions of up to 37% in major CV events and up to 48% in stroke risk, with effective lowering of LDL-C to target levels. Current clinical guidelines recommend targeted approaches to minimize cardiovascular complications in diabetes and chronic kidney disease (CKD) patients.